Payment overview · 2025
General Payments
$151.53
8 reported records · 7 companies
Healthcare provider profile · identity verified
Brian G Comer, D.O.
Allopathic & Osteopathic Physicians|Family Medicine · MULVANE, KS · NPI 1538155205
Verified facts
What the public records show
CMS Open Payments records show Brian G Comer, D.O. received $151.53 in general payments during 2025 across 8 reported records.
AstraZeneca Pharmaceuticals LP accounted for 22.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 141 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.38 | 22.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $29.65 | 19.6% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $23.12 | 15.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.35 | 12.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.83 | 10.4% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $15.68 | 10.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.52 | 9.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $151.53 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $29.65 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $29.65 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $23.12 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $19.45 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.35 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $15.83 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $15.68 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.52 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 141 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
141 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
108 | 28 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 634 | 163 |
| Amlodipine Besylate | Amlodipine Besylate | 411 | 94 |
| Levothyroxine Sodium | Levothyroxine Sodium | 376 | 97 |
| Lisinopril | Lisinopril | 350 | 91 |
| Jardiance | Empagliflozin | 343 | 67 |
| Omeprazole | Omeprazole | 270 | 66 |
| Gabapentin | Gabapentin | 222 | 46 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 210 | 42 |
| Sertraline Hcl | Sertraline Hcl | 175 | 37 |
| Losartan Potassium | Losartan Potassium | 161 | 45 |
| Meloxicam | Meloxicam | 153 | 36 |
| Metoprolol Tartrate | Metoprolol Tartrate | 143 | 32 |
| Ozempic | Semaglutide | 141 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 133 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 132 | 29 |
| Zolpidem Tartrate | Zolpidem Tartrate | 132 | 24 |
| Simvastatin | Simvastatin | 128 | 35 |
| Metformin Hcl | Metformin Hcl | 120 | 33 |
| Clopidogrel | Clopidogrel Bisulfate | 116 | 33 |
| Eliquis | Apixaban | 108 | 28 |
| Alendronate Sodium | Alendronate Sodium | 107 | 27 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 106 | 38 |
| Tizanidine Hcl | Tizanidine Hcl | 105 | 30 |
| Prednisone | Prednisone | 103 | 85 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 32 |
| Potassium Chloride | Potassium Chloride | 101 | 27 |
| Alprazolam | Alprazolam | 93 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 91 | 16 |
| Ipratropium Bromide | Ipratropium Bromide | 85 | 59 |
| Trazodone Hcl | Trazodone Hcl | 84 | 13 |
| Carvedilol | Carvedilol | 82 | 23 |
| Metoprolol Succinate | Metoprolol Succinate | 82 | 28 |
| Celecoxib | Celecoxib | 77 | 21 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 76 | 15 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 75 | 33 |
| Warfarin Sodium | Warfarin Sodium | 65 | 13 |
| Atenolol | Atenolol | 64 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 62 | 16 |
| Furosemide | Furosemide | 60 | 18 |
| Telmisartan | Telmisartan | 60 | 24 |
| Escitalopram Oxalate | Escitalopram Oxalate | 59 | 18 |
| Montelukast Sodium | Montelukast Sodium | 59 | 22 |
| Tramadol Hcl | Tramadol Hcl | 59 | 11 |
| Oxycodone Hcl | Oxycodone Hcl | 58 | suppressed |
| Topiramate | Topiramate | 58 | 13 |
| Hydrochlorothiazide | Hydrochlorothiazide | 55 | 13 |
| Methylprednisolone | Methylprednisolone | 55 | 52 |
| Famotidine | Famotidine | 53 | 13 |
| Morphine Sulfate Er | Morphine Sulfate | 53 | suppressed |
| Chlorthalidone | Chlorthalidone | 52 | 13 |
| Xarelto | Rivaroxaban | 52 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 49 | suppressed |
| Pregabalin | Pregabalin | 47 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | suppressed |
| Memantine Hcl | Memantine Hcl | 46 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 44 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 44 | suppressed |
| Allopurinol | Allopurinol | 43 | 15 |
| Pravastatin Sodium | Pravastatin Sodium | 42 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 14 |
| Metformin Hcl Er | Metformin Hcl | 41 | 12 |
| Clonazepam | Clonazepam | 40 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 40 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Mirtazapine | Mirtazapine | 37 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Baclofen | Baclofen | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Ezetimibe | Ezetimibe | 33 | suppressed |
| Novolog Flexpen | Insulin Aspart | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 32 |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Diazepam | Diazepam | 31 | 11 |
| Farxiga | Dapagliflozin Propanediol | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 23 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 29 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | 11 |
| Lorazepam | Lorazepam | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 28 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 28 | suppressed |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 27 | suppressed |
| Sucralfate | Sucralfate | 27 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | 12 |
| Humalog Kwikpen U-100 | Insulin Lispro | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 25 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 24 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 23 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 23 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 22 | 16 |
| Nystatin | Nystatin | 22 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Fluconazole | Fluconazole | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 13 |
| Clonidine Hcl | Clonidine Hcl | 18 | suppressed |
| Methotrexate | Methotrexate Sodium | 18 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Vascepa | Icosapent Ethyl | 18 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 17 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 17 | suppressed |
| Trulicity | Dulaglutide | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 16 | 11 |
| Folic Acid | Folic Acid | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 15 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 14 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 13 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 11 | suppressed |
| Glimepiride | Glimepiride | 11 | suppressed |
| Lagevrio (Eua) | Molnupiravir | 11 | 11 |
| Levemir Flexpen | Insulin Detemir | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Risperidone | Risperidone | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $151.53 · 8 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, Doc Band, Kerendia, NURTEC ODT, Omnipod, Ozempic, Rybelsus, ZAVZPRET, ZORYVE | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error